Ticker history: KTRA became HURA (TuHURA Biosciences, Inc.) on . Earlier news and filings retain their original names and dates. View KTRA history.
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HURA SEC filings page.
TuHURA Biosciences, Inc. (HURA) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
TuHURA remains a development-stage cash consumer, with expanding R&D commitments and financing needed alongside operating losses.
FY2025 operating cash flow of-$27.6M was close to the net loss of$30.1M , so reported losses were translating into cash use rather than being mainly accounting charges. Free cash flow of-$27.7M despite just$76K of capital expenditures reinforces that the cash demand is operating investment, not a heavy physical-asset build.
R&D increased
FY2025 financing cash flow of
Financial Health Signals
We do not publish a peer-relative financial health score for TuHURA Biosciences, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
TuHURA Biosciences, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.
TuHURA Biosciences, Inc. reported a net loss of $30.1M while operations used $27.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
TuHURA Biosciences, Inc. reported a net loss of $6.4M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
TuHURA Biosciences, Inc. earned -$0.10 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Not reported for Q3 2026.
Cash & Balance Sheet
TuHURA Biosciences, Inc. recorded an outflow of $5.0M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
TuHURA Biosciences, Inc. held $1.9M in cash against $9.2M in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
TuHURA Biosciences, Inc.'s quarterly ROE was -33.8% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 8.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 16.0 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
TuHURA Biosciences, Inc. invested $3.7M in research and development in Q3 2026. This represents a decrease of 25.4% from the same quarter a year earlier. Against the prior quarter it is down 44.0%.
TuHURA Biosciences, Inc. reported no capital expenditure in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 100.0%.
Not reported for Q3 2026.
HURA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $0n/m | N/A | N/A | N/A | $0n/m | N/A |
| R&D Expenses | $3.7M-25.4% | $6.6M+34.4% | $5.2M+14.2% | $6.1M+52.3% | $5.0M+68.6% | $4.9M+74.5% | $4.6M+27.7% | $4.0M |
| SG&A Expenses | $2.0M+22.8% | $2.1M+15.1% | $2.3M+13.9% | $2.1M | $1.6M+103.3% | $1.9M+134.0% | $2.0M+98.3% | N/A |
| Interest Expense | $753K+4451.8% | $468Kn/m | $28K | N/A | $17K-99.2% | $0-100.0% | N/A | $523K |
| Net Income | -$6.4Mn/m | -$9.2Mn/m | -$7.5Mn/m | -$6.8Mn/m | -$7.1Mn/m | -$9.5Mn/m | -$6.7Mn/m | -$6.0M |
| EPS (Basic) | -$0.10n/m | -$0.14n/m | -$0.13n/m | -$0.13 | -$0.14 | -$0.21 | -$0.15 | N/A |
| EPS (Diluted) | -$0.10n/m | -$0.14n/m | -$0.13n/m | -$0.13 | -$0.14 | -$0.21 | -$0.15 | N/A |
| Diluted Shares (Avg) | 65M+28.3% | 64M+43.6% | 60M+38.3% | N/A | 51M | 45M | 43M | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Operating Income, EBITDA, Income Tax.
HURA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'25Filing | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $36.2M+41.0% | $31.7M-8.3% | $29.7M+102.9% | $27.4M+37.0% | $25.7M+520.7% | $34.6M+458.2% | $14.6M+96.6% | $20.0M+401.8% |
| Current Assets | $3.7M+5.2% | $1.7M-86.8% | $7.0M-51.3% | $4.6M-76.4% | $3.5M+0.6% | $12.5M+126.8% | $14.3M+112.1% | $19.6M+499.7% |
| Cash & Equivalents | $1.9M-29.8% | $996K-88.3% | $6.3M+1.3% | $3.6M-71.4% | $2.7M | $8.5M | $6.2M+39.4% | $12.7M+724.6% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $10.7M-20.8% | $10.7M-20.8% | $10.7M | $10.7M | $13.6M | $13.6M | N/A | N/A |
| Total Liabilities | $17.3M+93.9% | $13.2M-12.7% | $6.5M+36.2% | $6.4M+19.5% | $8.9M+264.8% | $15.2M+520.5% | $4.8M+213.8% | $5.4M+65.4% |
| Current Liabilities | $7.8M-12.2% | $9.3M-39.0% | $6.1M+26.9% | $5.9M+11.1% | $8.8M+291.4% | $15.2M+571.6% | $4.8M+256.6% | $5.3M+72.9% |
| Non-Current Liabilities | $9.5M+11116.3% | $4.0Mn/m | $448Kn/m | $502K+1074.6% | $85K-54.8% | $0-100.0% | $0-100.0% | $43K-74.3% |
| Long-Term Debt | $9.2M | $3.6M | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $19.0M+13.0% | $18.5M-4.9% | $23.2M+135.3% | $20.9M+43.4% | $16.8Mn/m | $19.4Mn/m | $9.9Mn/m | $14.6M+1896.4% |
| Retained Earnings | -$164.4Mn/m | -$157.9Mn/m | -$148.7Mn/m | -$141.2Mn/m | -$134.4Mn/m | -$127.3Mn/m | -$117.8Mn/m | -$111.1Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable.
HURA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.0Mn/m | -$8.6Mn/m | -$4.4Mn/m | -$5.6Mn/m | -$11.1Mn/m | -$6.2Mn/m | -$4.7Mn/m | -$2.6M |
| Depreciation & Amortization | $27K+27.2% | $28K+110.2% | $23K+67.0% | $23K+27.8% | $21K-26.9% | $13K-62.5% | $14K-59.0% | $18K |
| Stock-Based Compensation | N/A | N/A | $2.8M+96.3% | N/A | N/A | N/A | $1.4M+325.8% | N/A |
| Capital Expenditures | $0n/m | $137K+2363.2% | $49K+14.5% | $28K+30.1% | $0n/m | $6K | $43K | $21K |
| Free Cash Flow | -$5.0Mn/m | -$8.8Mn/m | -$4.5Mn/m | -$5.6Mn/m | -$11.1Mn/m | -$6.3M | -$4.8M | -$2.6M |
| Investing Cash Flow | $0n/m | -$137Kn/m | -$49Kn/m | -$28Kn/m | $0n/m | -$156K | -$1.2Mn/m | -$824K |
| Financing Cash Flow | $5.9M+12.0% | $3.5M-60.1% | $7.1Mn/m | $6.5Mn/m | $5.3M-66.4% | $8.7M-32.8% | -$548K-111.8% | -$3.5M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
HURA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -33.8%+8.5pp | -49.9%-0.9pp | -32.5%+35.1pp | -32.3%+8.8pp | -42.3% | -49.0% | -67.6% | -41.1% |
| Return on Assets | -17.7%+10.0pp | -29.0%-1.5pp | -25.4%+20.2pp | -24.7%+5.3pp | -27.6%+107.1pp | -27.5%+57.4pp | -45.5%+19.5pp | -30.0% |
| Current Ratio | 0.48+0.1x | 0.18-0.6x | 1.15-1.8x | 0.78-2.9x | 0.40-1.1x | 0.83-1.6x | 3.00-2.0x | 3.68+2.6x |
| Debt-to-Equity | 0.49 | 0.19 | N/A | N/A | N/A | N/A | N/A | N/A |
| Liabilities-to-Equity | 0.91+0.4x | 0.72-0.1x | 0.28-0.2x | 0.31-0.1x | 0.53 | 0.78 | 0.49 | 0.37-4.1x |
| Asset Turnover | N/A | N/A | 0.000.0x | N/A | N/A | N/A | 0.000.0x | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: The current ratio is below 1.0 (0.78), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| TuHURA Biosciences, Inc. HURA | FY2025 | $0 | -$30.1M | N/A | $89.4M | — |
| PMV Pharmaceuticals, Inc PMVP | FY2025 | N/A | -$77.7M | N/A | $99.0M | — |
| Genelux Corporation GNLX | FY2025 | $8K | -$32.1M | N/A | $109.6M | — |
| Coherus Oncology, Inc. CHRS | FY2025 | $42.2M | $168.0M | N/A | $59.8M | 30/100 |
| Kazia Therapeutics Limited KZIA | FY2025 | $28K | -$13.6M | N/A | $83.5M | — |
| Vivani Medical, Inc. VANI | FY2025 | $0 | -$26.6M | N/A | $98.3M | — |
Where TuHURA Biosciences, Inc. Ranks
Frequently Asked Questions
TuHURA Biosciences, Inc. (HURA) reported $0 in total revenue for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
No, TuHURA Biosciences, Inc. (HURA) reported a net loss of $30.1M in fiscal year 2025.
TuHURA Biosciences, Inc. (HURA) has a return on equity of -143.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
TuHURA Biosciences, Inc. (HURA) recorded an outflow of $27.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
TuHURA Biosciences, Inc. (HURA) recorded an outflow of $27.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
TuHURA Biosciences, Inc. (HURA) had $27.4M in total assets as of fiscal year 2025, including both current and long-term assets.
TuHURA Biosciences, Inc. (HURA) invested $76K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
TuHURA Biosciences, Inc. (HURA) invested $20.5M in research and development during fiscal year 2025.
TuHURA Biosciences, Inc. (HURA) had a current ratio of 0.78 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
TuHURA Biosciences, Inc. (HURA) had a liabilities-to-equity ratio of 0.31 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
TuHURA Biosciences, Inc. (HURA) had a return on assets of -109.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
TuHURA Biosciences, Inc. (HURA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $89.4M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
TuHURA Biosciences, Inc. (HURA) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $89.4M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, TuHURA Biosciences, Inc. (HURA) held $3.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $27.6M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
TuHURA Biosciences, Inc. (HURA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
TuHURA Biosciences, Inc. (HURA) reported a net loss of $30.1M while operations used $27.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.